PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. has successfully conducted its annual general and special meeting, with shareholders approving all proposed resolutions, including the reappointment of their auditor and various corporate governance enhancements. The company, which is advancing in the psychedelic pharmaceuticals sector, anticipates significant developments by the upcoming FDA priority review date for their MDMA product. Additionally, PharmAla has announced a new round of RSU grants and is generating revenue through research services, while not disclosing the details of a significant purchase order for their MDMA product.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
